Large endometrial polyp with sarcomatous stromal components following long-term tamoxifen treatment for breast cancer: a case report and review of the literature

Tamoxifen is commonly used in the management of patients with breast cancer because of its anti-oestrogenic effects to the breasts. However, tamoxifen acts as an oestrogen agonist on the endometrium increasing the incidence of endometrial polyps, hyperplasia and cancer. In addition, it may be possible that tamoxifen increases the occurrence of uterine body tumours. We describe a rare case of a large endometrial polyp with sarcomatous stromal components in a 73-year-old breast cancer patient treated daily with 20 mg of tamoxifen for four years. The glands of the polyp were lined by benign appearing epithelium. The polyp was twisted and protruded from a dilated cervix at the entrance of the vagina. The patient was treated by removal of the polyp and dilatation and curretage. A postoperative computed tomography scan showed many focal hypodense lesions in the hepatic lobes with a well-defined profile suggestive of metastatic disease and the patient was referred for combined chemotherapy. In conclusion, a case of a mesenchymal malignant neoplasm arising in the uterus of a breast cancer patient treated with tamoxifen is reported and its clinical, histological and immunohistochemical features are discussed. Also, the international literature is reviewed.

Uterus; Polyp; Tamoxifen; Sarcoma; Mesenchymal tumours

[1] Early Breast Cancer Trialists'Collaboration Group:'Tamoxifen for early breast cancer: an overview of the randomized trials". Lancet, 1998, 351, 1451.

[2] Jordan V.C.: "Tamoxifen: Breast Cancer Update: Antiestrogens Past, present, and future. A roundtable discussion". Zeneca Pharmacuticals, 1996.

[3] Schlesinger C., Silverberg S.G.: "Tamoxifen-associated polyps (basalomas) arising in multiple endometriotic foci: A case report and review of the literature". Gynecol. Oneal., 1999, 73, 305.

[4] Fisher B., Dignam J., Wilmark N., DeCellis A., Emir B., Wickerman L. et al.:'Tamoxifen and chemotherapy for lymph node negative, estrogen receptor positive breast cancer". J. Natl. Cancer Inst., 1996, 88, 1529.

[5] Seoud M., Shamseddine A., Khalil A., Salem Z., Saghir N., Bikhazi K. et al.: "Tamoxifen and endometrial pathologies: a prospective study". Gynecol. Oneal., 1999, 75, 15.

[6] Love R.R.:'Tamoxifen prophylaxis in breast cancer". Oncology, 1992, 6, 33.

[7] Love R.R.:'Tamoxifen therapy in primary breast cancer: biology, efficacy and side effects". J. Clin. Oneal., 1989, 7, 803.

[8] Killachey M.A., Hakes TB., Pierce V.K.: "Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens". Cancer Treat. Rep., 1985, 69, 237.

[9] Varras M., Polyzos D., Akrivis Ch.: "Effects of tamoxifen on the human female genital tract: review of the literature". Eur. J Gynaecol. Oncol., 2003, 24, 258.

[10] De Muylder X., Neven P., De Somer M., Van Belle Y., Vanderick G., De Muylder E.: "Endometrial lesions in patient undergoing tamoxifen therapy". Int. J. Gynecol. Obstet., 1991, 36, 127.

[11] Bocklage T., Lee K.R., Belinson J.L.: "Uterine Miillerian adenosarcoma following adenomyoma in a woman on tamoxifen therapy". Gynecol. Oncol., 1992, 44, 104.

[12] Treilleux I., Mignotte H., Clement-Chassagne C., Guastalla P., Bailly C.: "Tamoxifen and malignant epithelial-nonepithelial tumors of the endometrium: report of six cases and review of the literature". Eur. J. Surg. Oneal., 1999, 25, 477.

[13] Fotiou S., Hatjieleftheriou G., Kyrousis G., Kokka F., Apostolakis N.: "Long-term tamoxifen treatment: a possible aetiological factor in the development of uterine carcinosarcoma: Two case-reports and review of the literature". Anticancer Research, 2000, 20, 2015.

[14] Pautier P., Genestie C., Ray A., Morice Ph., Roche B., Lhomme C et al.: "Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma". Cancer, 2000, 88, 1425.

[15] Clement P.B.,S cully R.E.: "Miillerian adenosarcoma of the uterus: A clinicopathological analysis of ten cases of a distinctive type of Miillerian mixed tumor". Cancer, 1974, 34, 1138.

[16] Zaloudek C., Norris H.J.: "Mesenchymal tumors of the uterus". In. "Blaustein's Pathology of the Female Genital Tract". 4'h ed., Kurman R.J. (ed.), New York, Springer-Verlag, 1987, 487.

[17] Carvalho F.M., Carvalho J.P., da Motta V., Souen J.: "Miillerian adenosarcoma of the uterus with sarcomatous overgrowth following tamoxifen treatment for breast cancer". Rev. Hosp. CUn. Fae. Med. S. Paulo, 2000, 55, 17.

[18] Arici D.S., Aker H., Yildiz E., Tasyurt A.: "Mullerian adenosarcoma of the uterus associated with tamoxifen therapy". Arch. Gynecol. Obstet., 2000, 264, 105.

[19] Clement P.B., Scully R.E.: "Mullerian adenosarcoma of the uterus- A clinicopathologic analysis of 100 cases with a review of the literature". Hum. Pathol., 1990, 21, 363.

[20] Oda Y., Nakanishi I., Tatewa T.: "Intramural Mullerian adenosarcoma of the uterus with adenomyosis". Arch. Pathol. Lab. Med., 1984, 108, 798.

[21] Gal D., Kerner H., Beck D., Peretz A., Eyal A., Paldi E.: "Case reports: Mullerian adenosarcoma of the cervix". Gynecol. Oncol., 1988, 31, 445.

[22] Kerner H., Lichtig C., Beck D.: "E xtrauterine Mullerian adenosarcoma of the peritoneal mesothelium - A clinicopathologic and electron microscopic study". Obstet. Gyneco/., 1989, 73, 510.

[23] Buckley C.H., Fox H.: "Miscellaneous benign conditions of the endometrium". In: "Biopsy Pathology of the Endometrium". Buckley C.H., Fox H. (eds.), London, Chapman and Hall, 1989, 131.

[24] Ramodetta L.M., Sherwood J.B., Dunton C.J., Palazzo J.P.: "Endometrial cancer in polyps associated with tamoxifen use". Am. J. Obstet. Gynecol., 1999, 180, 340.

[25] Lahti E., Blanco G., Kanppila A., Apaja-Sarkkinen M., Taskmen P.J., Laatikainen T.: "Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen". Obstet. Gynecol., 1993, 81, 660.

[26] Bera] Y.: "Prevention of cancers of the female genital tract". In The Biology of Gynaecological Cancer. Leake R., Gore M., Ward R.H. (eds.), London, RCOG Press, 1995, 217.

[27] Adami H.-0., Krusemo U.B., Bergkvist L., Persson I., Pettersson B.: "On the age-dependent association between cancer of the breast and the endometrium. A nationwide cohort study". Br. J Cancer, 1987, 55, 77.

[28] Stears V., Gelmann E.P.: "Does tamoxifen cause cancer in humans?". J. Clin. Oneal., 1998, 16, 779.

[29] Tosi P., Sforza V., Santopietro R.: "Estrogen receptor content. immunohystochemically determined by monoclonal antibodies in endometrial stromal sarcoma". Obstet. Gynecol., 1989, 73, 75.

[30] Aderson E., Howell A.: "The molecular biology of endocnne responsiveness in breast cancer". In: Molecular biology for Oncologists. Yamold J.R., Stratton M., McMillan T.J. (eds.). London, Chapman & Hall, 2"'ed., 1996, 217.

[31] Varras M., Spandidos D.A.: "Molecular biology of gynaecological cancer". In: Gynecological Oncology (in Greek). Pektasidis D., Demopoulos M-A. (eds.). Athens, Medical publications Paschalidis P., 2001, 68.

[32] Varras M.N., Zachos G., Spandidos D.A.: "Endometrial carcmoma in a breast cancer patient treated with tamoxifen: Activation of K-ras proto-oncogene". Oneal. Rep., 1997, 4, 1045.